{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:33:51Z","timestamp":1794105231760,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112363","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T02:51:32Z","timestamp":1635389492000},"page":"112363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans"],"prefix":"10.1016","volume":"144","author":[{"given":"Christine","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke M.","family":"Brussee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Pouzol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette E.","family":"Meyer zu Schwabedissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia N.","family":"Sidharta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2021.112363_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.dci.2011.01.019","article-title":"A family tree of vertebrate chemokine receptors for a unified nomenclature","volume":"35","author":"Nomiyama","year":"2011","journal-title":"Dev. Comp. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112363_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/84209","article-title":"Chemokines and disease","volume":"2","author":"Gerard","year":"2001","journal-title":"Nat. Immunol."},{"issue":"37","key":"10.1016\/j.biopha.2021.112363_bib3","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1073\/pnas.0702229104","article-title":"Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12\/SDF-1 receptor, CXCR7","volume":"104","author":"Sierro","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2021.112363_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105092","article-title":"Relevance of the CXCR4\/CXCR7-CXCL12 axis and its effect in pathophysiological conditions","volume":"161","author":"Huynh","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.112363_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/imm.12176","article-title":"Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels","volume":"141","author":"Berahovich","year":"2014","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.biopha.2021.112363_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1073\/pnas.0912852107","article-title":"\u03b2-arrestin- but not G protein-mediated signaling by the \u201cdecoy\u201d receptor CXCR7","volume":"107","author":"Rajagopal","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.112363_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009175","article-title":"CXCR7 functions as a scavenger for CXCL12 and CXCL11","volume":"5","author":"Naumann","year":"2010","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.biopha.2021.112363_bib8","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1093\/emboj\/16.23.6996","article-title":"Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1","volume":"16","author":"Crump","year":"1997","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.biopha.2021.112363_bib9","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1084\/jem.20052144","article-title":"A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development","volume":"203","author":"Burns","year":"2006","journal-title":"J. Exp. Med."},{"issue":"February","key":"10.1016\/j.biopha.2021.112363_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cyto.2018.02.024","article-title":"Emerging roles of atypical chemokine receptor 3 (ACKR3) in normal development and physiology","volume":"109","author":"Quinn","year":"2018","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semcdb.2012.03.009","article-title":"Attractive guidance: How the chemokine SDF1\/CXCL12 guides different cells to different locations","volume":"23","author":"Lewellis","year":"2012","journal-title":"Semin Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.conb.2008.06.004","article-title":"CXCL12\/CXCR4 signalling in neuronal cell migration","volume":"18","author":"Tiveron","year":"2008","journal-title":"Curr. Opin. Neurobiol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112363_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.20102010","article-title":"CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity","volume":"208","author":"Cruz-Orengo","year":"2011","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.112363_bib14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1084\/jem.20131224","article-title":"Targeting CXCR7\/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system","volume":"211","author":"Williams","year":"2014","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.112363_bib15","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.4049\/jimmunol.1601682","article-title":"The pivotal role of CXCR7 in stabilization of the pulmonary epithelial barrier in acute pulmonary inflammation","volume":"198","author":"Ngamsri","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib16","first-page":"3633","article-title":"CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro","volume":"17","author":"Qian","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2021.112363_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/bjc.2013.830","article-title":"Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats","volume":"110","author":"Walters","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.biopha.2021.112363_bib18","doi-asserted-by":"crossref","first-page":"15864","DOI":"10.1021\/acs.jmedchem.0c01588","article-title":"Discovery of the potent, selective, orally available CXCR7 antagonist ACT-1004-1239","volume":"63","author":"Richard-Bildstein","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.112363_bib19","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/cpt.2154","article-title":"A multipurpose first\u2010in\u2010human study with the novel CXCR7 antagonist ACT\u20101004\u20131239 using CXCL12 plasma concentrations as target engagement biomarker","volume":"109","author":"Huynh","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.202002465R","article-title":"ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases","volume":"35","author":"Pouzol","year":"2021","journal-title":"FASEB J."},{"issue":"15 Supplement","key":"10.1016\/j.biopha.2021.112363_bib21","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1212\/WNL.96.15_supplement.2236","article-title":"CXCR7 antagonism with ACT-1004-1239 reduces Neuroinflammation and accelerates Remyelination in murine demyelinating models (2236)","volume":"96","author":"Pouzol","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112363_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10928-010-9175-z","article-title":"The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects","volume":"38","author":"Chan","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib23","first-page":"1039","article-title":"Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party","volume":"29","author":"Gough","year":"1995","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1","key":"10.1016\/j.biopha.2021.112363_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: Part 3-introduction to pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib26","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.biopha.2021.112363_bib27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1534-5807(03)00321-6","article-title":"The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4","volume":"5","author":"Marchese","year":"2003","journal-title":"Dev. Cell."},{"issue":"26","key":"10.1016\/j.biopha.2021.112363_bib28","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1074\/jbc.273.26.15883","article-title":"Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4","volume":"273","author":"Tarasova","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2021.112363_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/cmi.2017.107","article-title":"The unique structural and functional features of CXCL12","volume":"15","author":"Janssens","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.biopha.2021.112363_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bcp.2017.03.009","article-title":"Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes","volume":"132","author":"Janssens","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112363_bib31","doi-asserted-by":"crossref","first-page":"986","DOI":"10.4049\/jimmunol.178.2.986","article-title":"Identification of CXCL11 as a STAT3-dependent gene induced by IFN","volume":"178","author":"Yang","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2021.112363_bib32","unstructured":"Bethesda (MD): National Library of Medicine (US); National Center for Biotechnology Information; 2004. Gene CXCL12C-X-C motif chemokine ligand 12 [ Homo sapiens (human)]. https:\/\/www.ncbi.nlm.nih.gov\/gene\/6387. (accessed 24 September 2021)."},{"key":"10.1016\/j.biopha.2021.112363_bib33","unstructured":"Bethesda (MD): National Library of Medicine (US); National Center for Biotechnology Information; 2004. Gene CXCL11C-X-C motif chemokine ligand 11 [ Homo sapiens (human)]. https:\/\/www.ncbi.nlm.nih.gov\/gene\/6373. (accessed 24 September 2021)."},{"issue":"3","key":"10.1016\/j.biopha.2021.112363_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22031038","article-title":"Racial disparity in drug disposition in the digestive tract","volume":"22","author":"Gao","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.112363_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2021.112363_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2156-14-34","article-title":"Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa","volume":"14","author":"Bains","year":"2013","journal-title":"BMC Genet."},{"issue":"1","key":"10.1016\/j.biopha.2021.112363_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s002280050413","article-title":"Adverse events in phase-I studies: a report in 1015 healthy volunteers","volume":"54","author":"Sibille","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112363_bib38","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/jcph.282","article-title":"Baseline and new-onset morphologic ECG abnormalities in healthy volunteers in phase I studies receiving placebo: changes over a 6-week follow-up period","volume":"54","author":"Hingorani","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112363_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061324","article-title":"QT assessment in early drug development: the long and the short of it","volume":"20","author":"Lester","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2021.112363_bib40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40264-015-0325-5","article-title":"Implications of the IQ-CSRC prospective study: time to revise ICH E14","volume":"38","author":"Darpo","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2021.112363_bib41","unstructured":"Laetitia Pouzol Anna Sassi Nad\u00e8ge Baumlin Daniel Tunis Daniel Strasser Fran\u00e7ois Lehembre Marianne Martinic CXCR7 antagonism reduces acute lung injury pathogenesis Frontiers in Pharmacology - Inflammation Pharmacology doi:\u00a010.3389\/fphar.2021.748740.In press."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:48:38Z","timestamp":1760100518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221011471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"alternative-id":["S0753332221011471"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112363","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112363"}}